Search research articles
Contact Us
Filters
Showing results (41-50 of 81) with videos related to
Page
of 9
Sort By:
Blood Advances
|
March 28, 2020
Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia
Edward Abadir, Pablo A Silveira, Robin E Gasiorowski, et al.
European Journal of Haematology
|
July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
Eric Wenlong Li, Esther Jones, Christian Bryant, et al.
Advances in Therapy
|
October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
Xu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Blood Advances
|
November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
Thierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
Transplantation and Cellular Therapy
|
January 8, 2025
Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More Therapies
Edward Abadir, Rebecca Wayte, Wenlong Li, et al.
Blood Advances
|
May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Peter Mollee, John Reynolds, Wojt Janowski, et al.
Asia-Pacific Journal of Clinical Oncology
|
March 23, 2026
Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
June 24, 2026
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study
Gemma K Reynolds, Mark R Dowling, Safia Belbachir, et al.
Molecular Oncology
|
July 25, 2019
CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation
Edward Abadir, Robin E Gasiorowski, Kaitao Lai, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 81) with videos related to
Sort By:
Page
of 9
Blood Advances
|
March 28, 2020
Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia
Edward Abadir, Pablo A Silveira, Robin E Gasiorowski, et al.
European Journal of Haematology
|
July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies
Eric Wenlong Li, Esther Jones, Christian Bryant, et al.
Advances in Therapy
|
October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
Xu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Blood Advances
|
November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
Thierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
Transplantation and Cellular Therapy
|
January 8, 2025
Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More Therapies
Edward Abadir, Rebecca Wayte, Wenlong Li, et al.
Blood Advances
|
May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Peter Mollee, John Reynolds, Wojt Janowski, et al.
Asia-Pacific Journal of Clinical Oncology
|
March 23, 2026
Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
June 24, 2026
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study
Gemma K Reynolds, Mark R Dowling, Safia Belbachir, et al.
Molecular Oncology
|
July 25, 2019
CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation
Edward Abadir, Robin E Gasiorowski, Kaitao Lai, et al.
Page
of 9